Nouscom
Clinical-stage biotech developing neoantigen-based cancer immunotherapies.
€120MSeries D
ParticipantCV
CDP Venture Capital
Activity from announced rounds
Activity in this selectionOct 21, 2026 · Sep 22, 2026
- Rounds participated in
- 3
- Confirmed lead rounds
- 1 All roles disclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $48.7M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionAptadir Therapeutics
RNA therapeutics designed to restore expression of silenced genes
€40MSeed
ParticipantClastix
Clastix builds Kubernetes infrastructure software, including Kamaji for hosted tenant control planes and kMetal for bare-metal cluster operations.
€2.9MSeed
Lead